Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Con...
March 04 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”,
“We”, “Our” or “Inotiv”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, today announced that Robert Leasure, Jr., President and
Chief Executive Officer, and Beth Taylor, Vice President of Finance
and Chief Financial Officer, are scheduled to participate in the
H.C. Wainwright Global Life Sciences Virtual Conference on March
9-10, 2021. Management will be available for one-on-one meetings
throughout both days. A webcast of the presentation will be
available on March 9, 2021, at 7:00 a.m. ET through a link that
will be posted on the Investors section of the Company’s
website at
ir.inotivco.com and will be
available for approximately 90 days.
About the Company
Bioanalytical Systems, Inc., doing business as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more information
about the Company.
This press release contains “forward looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties. Forward-looking statements speak only as of the date
they are made, and the Company undertakes no obligation to update
any of them publicly in light of new information or future events.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors. More
information, including potential risk factors, that could affect
the Company’s business and financial results are included in the
Company’s filings with the U.S. Securities and Exchange Commission,
including, but not limited to, the Company’s Forms 10-K, 10-Q and
8-K.
Company Contact |
Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Kalle Ahl, CFA |
(765) 497-8381 |
(212) 836-9614 |
btaylor@inotivco.com |
kahl@equityny.com |
|
|
|
Devin Sullivan |
|
(212) 836-9608 |
|
dsullivan@equityny.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024